Fcγ receptor 3B polymorphism is associated with hypersensitivity reactions to adalimumab in Japanese patients with rheumatoid arthritis.
OBJECTIVE
To examine the association between Fcγ receptor (FcγR) polymorphisms and the development of hypersensitivity reactions to adalimumab in patients with rheumatoid arthritis.


METHODS
Sixty-five patients receiving adalimumab were enrolled in the study. Genetic polymorphisms for FcγR3B were genotyped in FCGR3B NA1/2 alleles by real allelic discrimination assay. Clinical information and the occurrence of a hypersensitivity reaction to adalimumab were collected from the patients' charts.


RESULTS
A hypersensitivity reaction was observed in 12% of the patients. Clinical information obtained from patients with a reaction and those without were the same. The FCGR3B NA1/NA1, NA1/NA2, and NA2/NA2 alleles were found in 75%, 13%, and 13% of the patients with hypersensitivity reaction, respectively, and in 28%, 42%, and 30% of those without a hypersensitivity reaction, respectively (p = 0.04). Multivariate logistic regression analysis identified only the NA1/NA1 as an independent relevant factor for a hypersensitivity reaction to adalimumab (OR 7.7, p = 0.01).


CONCLUSIONS
The FCGR3B NA1/NA1 genotype is associated with hypersensitivity reactions to adalimumab.
a Division of Rheumatology, Department of Internal Medicine , Keio University School of Medicine , Tokyo , Japan and.
Masako
M
Tsukamoto
a Division of Rheumatology, Department of Internal Medicine , Keio University School of Medicine , Tokyo , Japan and.|b Division of Rheumatology, Department of Internal Medicine, School of Medicine , Toho University , Tokyo , Japan.
Hideto
H
Kameda
a Division of Rheumatology, Department of Internal Medicine , Keio University School of Medicine , Tokyo , Japan and.
Tatsuhiro
T
Ohshige
a Division of Rheumatology, Department of Internal Medicine , Keio University School of Medicine , Tokyo , Japan and.
Yuko
Y
Kaneko
a Division of Rheumatology, Department of Internal Medicine , Keio University School of Medicine , Tokyo , Japan and.
Keiko
K
Yoshimoto
a Division of Rheumatology, Department of Internal Medicine , Keio University School of Medicine , Tokyo , Japan and.
Katsuya
K
Suzuki
a Division of Rheumatology, Department of Internal Medicine , Keio University School of Medicine , Tokyo , Japan and.
Tsutomu
T
Takeuchi
D000068879:Adalimumab / Q000008:administration & dosage / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000235:genetics; D004342:Drug Hypersensitivity / Q000235:genetics*; D005260:Female; D058851:GPI-Linked Proteins / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006801:Humans; D000075662:Injection Site Reaction / Q000175:diagnosis / Q000209:etiology; D007564:Japan; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D017452:Receptors, IgG / Q000235:genetics*
D018501:Antirheumatic Agents; C428200:FCGR3B protein, human; D058851:GPI-Linked Proteins; D017452:Receptors, IgG; D000068879:Adalimumab
Adalimumab; Injection site reaction; Polymorphism; Rheumatoid arthritis